Background Uveitis associated with juvenile idiopathic arthritis is a cause of major ocular morbidity. A substantial proportion of children are refractory to systemic methotrexate and TNF inhibitors. Our aim was to study the safety and efficacy of tocilizumab in children with juvenile idiopathic arthritis-associated uveitis refractory to both methotrexate and TNF inhibitors.
Introduction
Juvenile idiopathic arthritis is an inflammatory arthritis that affects one in 1000 children. Children with juve nile idiopathic arthritis are also at risk of uveitis, an inflam mation of the uvea in the eye. Up to 80% of all paedi atric uveitis is secondary to juvenile idiopathic arthritis. 1, 2 The development of juvenile idiopathic arthritis with uveitis is associated with early onset of arthritis, an oligoarticu lar pattern of arthritis, and presence of anti nuclear antibodies. 3 Children with moderate to severe uveitis can be refractory to methotrexate. [4] [5] [6] [7] [8] In such patients, mono clonal TNF inhibitors, including adalimumab, are often effective. [9] [10] [11] [12] However, 30-40% 13 of patients are refractory to both methotrexate and TNF inhibitors and are there fore at great risk of significant ocular complications and blindness.
In patients with severe disease that does not respond to methotrexate and antiTNF drugs, strong evidence sup ports the approach of targeting interleukin6 (IL6) in the disease pathogenesis. [14] [15] [16] [17] [18] Therefore, a phase 2 trial of the potential efficacy, safety, and tolerability of the IL6 receptor inhibitor tocilizumab was done. In arthritis, IL6 causes tiredness, anaemia, and inflammation, as well as dam age to bones, cartilage, and tissue; tocilizumab reduces these effects. 19 Previous studies looking at the e136 www.thelancet.com/rheumatology Vol 2 March 2020 20 However, in a trial of tocilizumab in children with the systemic form of juve nile idiopathic arthritis who are unresponsive to metho trexate, patients responded dramatically to treatment in a short time span. 20 As a result, tocilizumab became the first drug licenced for use in juvenile idiopathic arthritis in 50 years; tocilizumab also obtained National Institute for Health and Care Excellence approval for this indication in 2011. An ongoing clinical trial is test ing tocilizumab in patients with polyarticular forms of juvenile idio pathic arthritis with good effect (NCT02165345). How ever, patients with juvenile idiopathic arthritisassociated uveitis have been excluded from these clinical trials, so the efficacy of tocilizumab in these patients is unclear. There fore, in the APTITUDE trial, we aimed to assess the safety and efficacy of tocilizumab in this paediatric population.
Methods

Study design
APTITUDE was a multicentre, singlearm, phase 2 trial that was done at seven tertiary hospital sites in the UK following a Simon's twostage design, 21 in which a small group of participants are recruited in the first stage, and the recruitment of another group of participants in stage 2 only commences if an adequate number of responses have been observed in the first stage (appendix p 1).
Ethical approval for the trial was provided by the National Research Ethics Service Committee London-South East on July 3, 2015 (reference number 15/LO/0771).
The protocol and statistical analysis plan are available online.
Patients
Children and young people aged 2-18 years of age who had active juvenile idiopathic arthritisassociated uveitis were eligible to take part in the trial. Active uveitis was defined based on the standardisation of uveitis nomen clature (SUN) criteria 22 as two or more readings of cellular infiltrate in anterior chamber cells of grade 1+ or greater (possible scores are 0, 0·5+, 1+, 2+, 3+, and 4+) during the 6 weeks preceding screening. Participants must have had an inadequate treatment response with at least one anti TNF drug and have been on at least one antiTNF drug (regardless of dose) for at least 12 weeks at any time before enrolment in the trial. They must have been on methotrexate for at least 12 weeks with a stable dose for 4 weeks before screening, without adequate response. Key exclusion criteria were previous exposure to tocili zumab; previous exposure in a clinical trial to another medicinal product such that the estimated level of the drug in the patient's blood was more than that predicted by 4 weeks or five halflives of the drug (whichever was longer); receipt of more than six topical glucocorticoid drops per eye per day at time of enrolment; and receipt of prednisone (or the equivalent) at a dose exceeding 0·2 mg/kg bodyweight per day. Patients who did not pass screening were able to be rescreened after a minimum of 1 week after their last screening. Full exclusion criteria are in the appendix (p 3). Each parent or guardian pro vided written informed con sent. Each child gave assent when appropriate.
Procedures
Patients received tocilizumab dosed according to body weight, with patients weighing 30 kg or more given
Research in context
Evidence before this study We reviewed an evidence synthesis review update in April, 2013, and before grant submission, prepared by Arthritis Research UK (now Versus Arthritis). The object of this report was to highlight recently completed and ongoing clinical trials in Paediatric Rheumatology. We found no studies related to tocilizumab and juvenile idiopathic arthritis-associated uveitis. We also searched ClinicalTrials.gov using the search terms "uveitis" and "tocilizumab". We found one open-label trial aiming to assess tocilizumab treatment in six patients with juvenile idiopathic arthritis-associated uveitis. The efficacy of tocilizumab in uveitis and ophthalmology outcomes had not been assessed before that study. However, the rationale for anti-IL-6 therapy is strong-in arthritis, IL-6 causes tiredness, anaemia, and inflammation and damage to bones, cartilage, and tissue. Tocilizumab blocks IL-6, reducing the symptoms. Hence, a phase 2 study is needed to give early indications of the clinical effectiveness of tocilizumab in combination with methotrexate and to decide whether further research is justified. Previous studies investigating the effect of tocilizumab in paediatric arthritis have excluded patients with uveitis. However, a study by Muselier and colleagues on tocilizumab in uveitis in adults showed its potential role for refractory disease. A previous systematic search by Adán and colleagues of existing data found only a couple of case reports.
Added value of this study
To our knowledge, this is first trial looking at efficacy of tocilizumab in juvenile idiopathic arthritis-associated uveitis. This study is able to give early indications of the potential clinical effectiveness of tocilizumab in combination with methotrexate for the treatment of children with refractory juvenile idiopathic arthritis-associated uveitis.
Implications of all the available evidence
This study provides evidence that tocilizumab might be a useful adjunctive therapeutic option for children with uveitis refractory to anti-TNF treatments. This study also provides evidence of efficacy in macular oedema associated with juvenile idiopathic arthritis uveitis, as reported in previous studies.
For the protocol and statistical analysis plan see http://www.uhbristol.nhs.uk/ research-innovation/ourresearch/grants-andinfrastructure-awards/ large-charitable-grants/aptitude/ 162 mg of subcutaneous tocilizumab every 2 weeks and patients weighing less than 30 kg given 162 mg of sub cutaneous tocilizumab every 3 weeks for 24 weeks. Patients weighing less than 30 kg were given a maximum of nine injections and patients weighing 30 kg or more were given a maximum of 13 injections. Injections were administered at hospital or by self administration at home depending on patient preference. Patients who missed two consecutive doses or three doses in total of tocilizumab injection ceased trial treatment and were recorded as a withdrawal from treatment. Treat ment compliance was measured using accountability logs and participant diaries. All participants were treated up to a maximum of 24 weeks and then followed up after treatment for 12 weeks and assessed per the trial assess ments (appendix p 2). All patients continued on metho trexate throughout trial participation.
Adverse events were collected up to 30 calendar days after cessation of treatment. Patients who did not achieve treatment response stopped treatment and proceeded to followup.
Outcomes
The primary outcome was response to treatment, defined according to SUN criteria 22 as a twostep decrease in score in the level of inflammation (anterior chamber cells) or decrease to zero between baseline and 12 weeks of treatment. Secondary outcomes included safety and tolerability of tocilizumab; compliance; corticosteroid use; optic and ocular outcomes; quality of life; American College of Rheumatology (ACR) pediatric 30, ACR pediatric 50, ACR pediatric 70, ACR pediatric 90, and ACR pediatric 100; numbers of participants with changes in biologic or diseasemodifying antirheumatic drugs; numbers of patients with arthritis flares; and juvenile arthritis disease activity score (JADAS). Details are in the appendix (pp 4-5).
Statistical analysis
The trial was done following a Simon's twostage design. 21 The null hypothesis (response 20% or lower) reflected a response rate of no clinical benefit whereas the alternative hypothesis (response at least 50%) reflects a desired response. If the true success probability was 20%, then the probability of success in further study of tocilizumab would be less than 5% (ie, falsely pursuing a non promising therapy). If the true success probability was 50% or more, then further study of tocilizumab in a phase 3 trial would be recommended, with a probability greater than 90% of showing a therapeutic effect of the drug (ie, correctly pursuing a promising therapy).
The interim and final sample sizes and the critical values for abandoning tocilizumab at each stage were chosen a priori as follows: the interim analysis sample size was ten patients, and the analysis was done after ten patients had provided primary outcome data at the 12week visit. Based on a critical interim value of two treatment responses (ie, if there were two or fewer treat ment responses then the trial would be stopped for futility), a sample size of 22 patients was needed for the full analysis, with a critical value of seven treatment responses (ie, if there were seven or fewer treatment responses, then it would be concluded that the further study of tocilizumab should be abandoned). If further study of the drug is not abandoned at either the interim or the final analysis, then a recommendation would be made to conduct a comparative, randomised phase 3 trial. The interim analysis was reviewed by the independent safety monitoring committee, who made recommendations to the trial steering committee whether to continue the trial or terminate it for futility.
Analyses was done according to the predefined statistical analysis plan and used the principle of intention to treat. If consent to treatment was withdrawn but the participant agreed to remain in the study for followup, the partici pant was followed up until 12 weeks after ceasing trial treatment. If the participant decided to withdraw consent completely, the reasons for withdrawal of consent were recorded (if possible) and reported.
For the primary outcome, the point estimate, CI, and p value were computed using the method described by Jovic and Whitehead. 23 Prespecified sensitivity analy ses tested the effects of missing data, participants who stopped their intervention early, and those who had been incorrectly identified as having treatment response. Trial oversight was provided by an independent data and safety monitor ing committee and a trial steering committee.
All analyses were done with SAS, version 9.3 or above. The trial was registered on the International Standard Randomised Controlled Trial Number registry (ISRCTN95363507) on June 10, 2015, and EU Clinical Trials Register on July 3, 2015 (EudraCT 201500132323).
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Results
Patients were recruited for the trial between Dec 3, 2015, and March 9, 2018. 44 patients were screened (58 screen ing events) at seven tertiary hospital sites in the UK (appendix p 20). 24 patients (32 screenings) did not meet the inclusion criteria and 26 patients met the inclusion criteria (six of these patients were deemed eligible after not meeting inclusion criteria at an earlier visit; figure) . The main reasons for ineligibility were absence of active anterior uveitis as defined in the protocol (17 [53%] of 32 screening events) and presence of clinically signi ficant deviations in laboratory parameters (four [13%]; appendix p 6). Four patients did not consent to take part in the trial. 22 participants were enrolled in the trial.
Particpants were aged 5-17 years and 18 (86%) were women (table 1) . All participants in the study had taken adalimumab and none had received other TNF inhibitors; additional demographic and baseline clinical information are in the appendix (pp [6] [7] [8] . Data for the primary outcome were available for all the participants except one, who was found to be ineligible immediately after enrolment; this patient was therefore not included in any of the analyses. 17 (81%) of 21 patients discontinued treatment before 24 weeks, six (29%) discontinued before their 12week visit, nine (43%) discontinued at 12 weeks, and two (10%) discontinued between weeks 12 and 24 (one because of nonresponse and the other because of a requirement for a nonpermitted medication to treat worsening ocular pressures). Treatment compliance was 92% according to the patient diaries and 80% according to accountability logs.
The results of the interim analysis were reported to the independent safety monitoring committee in November, 2016. Four (40%) of ten participants responded to treatment, indicating that the trial should continue.
Seven (33%) of 21 participants achieved treatment res ponse at week 12 (table 2). The median unbiased estimate of the proportion of treatment responses was 34% (95% CI 25-57; p=0·11). Of the six patients that discontinued treatment before week 12, one was classified as a treatment res ponse and the other five as nonresponders. 13 (62%) of 21 patients were classified as nonresponders, eight of whom reached 12 weeks of treatment. Of the six patients who continued treatment after 12 weeks, four (67%) were classed as treatment responders at 24 weeks.
The safety data set consisted of all 21 patients who received at least one dose of the study drug. A total of 175 adverse events were reported in 20 (95%) participants; no serious adverse events were reported during the trial (appendix pp 8-10). 21 adverse events of special interest in seven (33%) patients were collected during the trial (appendix p 10). The most frequent adverse events were injection site reaction (24 events Secondary outcome results are in the appendix (pp 10-18). Of 21 participants, four (19%) were receiving oral cortico steroids at baseline. Three of these patients were taking 5 mg per day or more at baseline, and none were able to reduce the dose to less than 5 mg per day (appendix p 10). 20 patients were using topical cortico steroid eye drops at baseline, 18 of whom who were on two or more drops per eye per day (appendix p 11). Three (17%) of these 18 patients were able to reduce use to less than two drops per eye per day. Three (15%) of 20 participants were able to completely stop use of corticosteroid eye drops.
Four (19%) patients had macular oedema at base line, which resolved after treatment in three patients. Two patients had glaucomatous neuropathy at baseline; this resolved during the course of the trial in one patient and the other patient developed neovascularisation, which subsequently resolved. No participants had complete dis ease control (as defined by SUN criteria 22 as zero cells) at week 12 or week 24 with topical treatment and sub cutaneous tocilizumab.
Quality of life data as measured by the child health questionnaire and childhood health assessment question naire were not clinically significant and arthritis disease activity measures (ACR pediatric and JADAS) scores did not change significantly (appendix pp [14] [15] [16] .
In a posthoc analysis, three (19%) patients had a partial response (onestep improvement) at the 24week visit (two patients had 12 weeks of treatment and one had 11 weeks).
The mean number of corticosteroid drops at baseline was 4·48 drops (SD 3·11), which reduced to 4·33 drops (2·29) at 12 weeks (appendix p 11). Foveal thickness split was also assessed posthoc and the mean number for best score was 278·6 (SD 67·68) reducing to 257·7 (51·73) at 24 weeks (appendix p 17).
Discussion
This Simon's twostage design study of participants with treatment refractory juvenile idiopathic arthritis associated uveitis did not meet the prespecified criterion (more than seven responses from 21 partici pants) at 12 weeks to justify a phase 3 trial. A third of the participants (seven [33%] of 21) had a twostep improvement in uveitis assessment at week 12 and a further three (14%) had a onestep improvement at week 24 with tocilizumab. Three of four participants had complete resolution of cystoid macular oedema in response to tocilizumab.
Tocilizumab is effective in polyarticular 20 and systemic juvenile idiopathic arthritis 24 as well as rheumatoid arthritis 25 and giant cell arteritis. 26 The STOPUveitis study, 14 an openlabel study of intravenous tocilizumab in adult patients with posterior segment uveitis, showed a red uction in vitreous haze and macular thickness. Improve ments in anterior chamber cell counts and macular thickening were seen in retrospective studies of intra venous tocilizumab in juvenile idiopathic arthritis uveitis and adult uveitis, including adult juvenile idio pathic arthritis. [15] [16] [17] [18] One study of tocilizumab in juvenile idiopathic arthritis used the juvenile idiopathic arthritis ACR pediatric 30 response at 12-16 weeks as the primary outcome, 20 which although not directly comparable to uveitis scores, are arguably a less robust response than a twostep decrease on the SUN inflammation score. Studies have also shown progressive improvements in uveitis activity 14 over 26 weeks and systemic juvenile idiopathic arthritis disease activity over 52 weeks 24 with tocilizumab. It is possible that the number of responders on tocilizumab would have been higher with a longer duration of treat ment, but it is also important to protect against the risks of a potentially ineffective treatment. Rapid disease control is important in uveitis, in which prolonged uveitis activity increases the risk of sight loss. 27 Subcutaneous tocilizumab was less effective than intravenous tocilizumab for juvenile idiopathic arthritis uveitis in a small case series, 28 but has shown similar efficacy to intravenous tocilizumab in randomised con trolled studies of rheumatoid arthritis. 29, 30 Subcutaneous therapies are more desirable than intravenous infusions for patient convenience, maximising school attendance and using fewer healthcare resources. The eye has blood aqueous and blood retinal barriers and so potentially higher doses of drug are required in the eye to gain therapeutic efficacy than at other body sites. 31 The paucity of clinical trials for paediatric uveitis combined with the availability of potential treatments through use in other rheumatic diseases has led to many immunosuppressive drugs being prescribed for paediatric uveitis and included in treatment guidelines with little evidence. 32 A strength of this study is the incorporation of the Simon design to identify molecules for further clinical study in patients with paediatric uveitis, with low risk to participants, and to enable the gathering of evidence and publication of results in a more systematic way than in case series and openlabel studies. Safety results were consistent with the known safety profile of intraven ous tocilizumab, with the exception of injection site reactions. 20, 24 Limitations of this study include the small sample size, absence of a control group, and severity of disease. With respect to severity of disease in this cohort, the patients enrolled displayed moderate anterior chamber inflam mation, and in some it was associated with cystoid macular oedema despite antiTNF and methotrexate therapy. Continuing inflammation in the face of sub stantial immunomodulatory therapy indicates a cohort of patients with moderate to severe disease overall. The 12week duration of the primary outcome might have underestimated the treatment efficacy, and no uveitis specific patientrecorded outcome measures were used. Macular oedema outcomes were limited to presence or absence of oedema and central macular thickness, which might vary on different optical coherence tomography machines. 33 Additionally, the results are not transferable to other formulations of tocilizumab and therefore the optimal method of administration for juvenile idiopathic arthritisassociated uveitis remains unclear. Finally, in this small study no stratification of molecular signatures was done to identify differences between responders and nonresponders.
In conclusion, subcutaneous tocilizumab did not meet its primary endpoint in this Simon design study. Efficacy signals for juvenile idiopathic arthritis uveitis were noted, including reduction of macular oedema, as rep orted in previous studies, but not at a sufficient level to warrant a phase 3 study. There might be merit in studying intra venous formulations of tocilizumab in a select predefined population of patients.
Although this study used the standard and validated measure of anterior chamber cell activity to assess the extent of inflammation, lower levels of persistent inflam mation that are more quantifiable by clinical assessment might be more useful for trials and going forward in clinical practice. Laser flare photometry, for example, was adopted in the Adjuvite study. 34 For patients with refractory uveitis not responsive to antiTNF drugs, other therapeutic approaches have been reported anecdotally, including checking for anti drug antibodies, weekly adalimumab abatacept, and JAKkinase inhibitors. [35] [36] [37] Tocilizumab might provide a valuable adjunc tive therapeutic option for children with uveitis ref ractory to antiTNF, particularly as adalimumab is the only evidencebased and licensed therapy. Although our study did not meet its primary endpoint, this is, to our know ledge, the only prospective study of tocilizumab.
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